CVA Family Office LLC Buys 181 Shares of Revvity Inc. $RVTY

CVA Family Office LLC boosted its stake in shares of Revvity Inc. (NYSE:RVTY) by 79.0% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 410 shares of the company’s stock after buying an additional 181 shares during the period. CVA Family Office LLC’s holdings in Revvity were worth $40,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. UMB Bank n.a. grew its position in shares of Revvity by 138.8% during the second quarter. UMB Bank n.a. now owns 406 shares of the company’s stock valued at $39,000 after purchasing an additional 236 shares in the last quarter. New Age Alpha Advisors LLC purchased a new position in Revvity during the 1st quarter valued at approximately $44,000. Caitong International Asset Management Co. Ltd grew its holdings in Revvity by 25.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 694 shares of the company’s stock valued at $73,000 after buying an additional 140 shares in the last quarter. Cary Street Partners Investment Advisory LLC bought a new stake in Revvity in the 1st quarter worth approximately $75,000. Finally, Banque Transatlantique SA raised its holdings in shares of Revvity by 19.4% during the 1st quarter. Banque Transatlantique SA now owns 925 shares of the company’s stock worth $90,000 after acquiring an additional 150 shares in the last quarter. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Revvity Price Performance

Revvity stock opened at $98.91 on Monday. Revvity Inc. has a 12-month low of $81.36 and a 12-month high of $129.50. The company has a current ratio of 3.33, a quick ratio of 2.75 and a debt-to-equity ratio of 0.43. The firm has a 50-day moving average price of $89.38 and a 200-day moving average price of $92.37. The firm has a market capitalization of $11.48 billion, a PE ratio of 41.91, a price-to-earnings-growth ratio of 3.30 and a beta of 0.98.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Monday, July 28th. The company reported $1.18 EPS for the quarter, beating the consensus estimate of $1.14 by $0.04. The company had revenue of $720.28 million for the quarter, compared to the consensus estimate of $711.26 million. Revvity had a net margin of 10.19% and a return on equity of 7.66%. The firm’s revenue was up 4.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.22 EPS. As a group, equities research analysts forecast that Revvity Inc. will post 4.94 EPS for the current year.

Revvity Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 6th. Stockholders of record on Friday, January 16th will be paid a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, January 16th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.3%. Revvity’s dividend payout ratio is currently 11.86%.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on RVTY. Robert W. Baird set a $122.00 price target on shares of Revvity in a research report on Friday. Guggenheim began coverage on shares of Revvity in a research note on Wednesday, October 15th. They issued a “neutral” rating for the company. Raymond James Financial restated an “outperform” rating and issued a $115.00 target price (down from $120.00) on shares of Revvity in a report on Tuesday, July 29th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Revvity in a report on Saturday. Finally, Evercore ISI dropped their price target on Revvity from $108.00 to $106.00 and set an “outperform” rating for the company in a research report on Tuesday, October 7th. Nine research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $116.38.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.